Reversan

Overview

Reversan (CBLC4H10) inhibits drug efflux mediated by P-glycoprotein (Pgp) and multidrug resistance protein 1 (MRP1) , and exhibits oral activity. Reversan shows activity against glioblastoma multiforme and neuroblastoma models.

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Ovarian Cancer | Products > Disease Areas > Urogenital Cancer | Products > Signaling Pathways > Membrane Transporter/Ion Channel | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Drug Resistance | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Signaling Pathways > P-glycoprotein

Product Information

• Catalog No.: HY-107643
• CAS No.: 313397-13-6
• Molecular Formula: C26H27N5O2
• Molecular Weight: 441.52
• Purity: 99.57%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: 1.56 mg/mL (3.53 mM); Suspended solution; Need ultrasonic
• Availability: In-stock

Source

Original product source